These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
716 related articles for article (PubMed ID: 19563866)
1. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866 [TBL] [Abstract][Full Text] [Related]
2. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Pang M; Martinez AF; Fernandez I; Balkan W; Troen BR Gene; 2007 Nov; 403(1-2):151-8. PubMed ID: 17897792 [TBL] [Abstract][Full Text] [Related]
3. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells. Pang M; Martinez AF; Jacobs J; Balkan W; Troen BR Biochem Biophys Res Commun; 2005 Mar; 328(3):756-63. PubMed ID: 15694411 [TBL] [Abstract][Full Text] [Related]
4. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts. Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407 [TBL] [Abstract][Full Text] [Related]
5. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway. Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related]
8. Activation of the beta myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway. Meissner JD; Umeda PK; Chang KC; Gros G; Scheibe RJ J Cell Physiol; 2007 Apr; 211(1):138-48. PubMed ID: 17111365 [TBL] [Abstract][Full Text] [Related]
9. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014 [TBL] [Abstract][Full Text] [Related]
10. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846 [TBL] [Abstract][Full Text] [Related]
11. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation. Tsuji-Naito K Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786 [TBL] [Abstract][Full Text] [Related]
12. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Kim JH; Kim K; Youn BU; Jin HM; Kim N Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061 [TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269 [TBL] [Abstract][Full Text] [Related]
14. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893 [TBL] [Abstract][Full Text] [Related]
15. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Crotti TN; Flannery M; Walsh NC; Fleming JD; Goldring SR; McHugh KP Gene; 2006 May; 372():92-102. PubMed ID: 16513293 [TBL] [Abstract][Full Text] [Related]
16. AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors. Pang M; Rodríguez-Gonzalez M; Hernandez M; Recinos CC; Seldeen KL; Troen BR J Cell Biochem; 2019 Aug; 120(8):12382-12392. PubMed ID: 30816596 [TBL] [Abstract][Full Text] [Related]
17. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ). Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059 [TBL] [Abstract][Full Text] [Related]
19. NFATc1 activates the acetylcholinesterase promoter in rat muscle. Cohen TV; Randall WR J Neurochem; 2004 Sep; 90(5):1059-67. PubMed ID: 15312161 [TBL] [Abstract][Full Text] [Related]
20. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis. Lee NK; Choi HK; Yoo HJ; Shin J; Lee SY Cell Signal; 2008 Dec; 20(12):2302-8. PubMed ID: 18796328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]